Investor Relations
Financial calendar
Q1 report
15/05/25Annual General Meeting
28/05/25Half-year report
21/08/25Q3 report
13/11/25Full-year report
05/02/26Annual Report for 2025
05/05/26
Latest press releases
ExpreS2ion files clinical trial amendment to enable combination testing of ES2B-C001 with antibody-drug conjugates and to expand the number of study sites
Hørsholm, Denmark, 13 May 2025 - ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”), a clinical-stage biotechnology company developing vaccine candidates for infectious diseases and cancer, today announced that it has submitted a study protocol amendment to the Austrian regulatory authorities to enable the evaluation of its breast cancer vaccine candidate, ES2B-C001, in combination with…
Read moreExpreS2ion to Present in Upcoming Investor Events
Hørsholm, Denmark, 9 May 2025 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce its participation in two key upcoming investor events: Bio€quity Europe and a webinar presentation of interim results for Q1 2025.
Read moreExpreS2ion annual report for 2024 published
Hørsholm, Denmark, 1 May 2025 - ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that the Annual Report for the financial year 2024 has been published. The Annual Report is available as an attachment to this press release and can be accessed on the Company’s website at: https://investor.expres2ionbio.com/reports/
Read moreLatest presentations
2024 Q4 and Full-Year
Report Webcast
6 February 2025
Stora Aktiedagarna
Stockholm
27 November 2024
Biostock
Life Science Summit
21 November 2024